A comprehensive immunohistochemical analysis of IMP2 and IMP3
in 542 cases of ovarian tumors

J 2023

A comprehensive immunohistochemical analysis of IMP2 and IMP3 in 542 cases of ovarian tumors

NEMEJCOVA, Kristyna, Michaela BARTU KENDALL, Romana MICHALKOVA, Jana DROZENOVA, Pavel FABIAN et. al.

Basic information

Original name

A comprehensive immunohistochemical analysis of IMP2 and IMP3 in 542 cases of ovarian tumors

Authors

NEMEJCOVA, Kristyna (203 Czech Republic, guarantor), Michaela BARTU KENDALL (203 Czech Republic), Romana MICHALKOVA (203 Czech Republic), Jana DROZENOVA (203 Czech Republic), Pavel FABIAN (203 Czech Republic), Oluwole FADARE (203 Czech Republic), Jitka HAUSNEROVÁ (203 Czech Republic, belonging to the institution), Jan LACO (203 Czech Republic), Radoslav MATEJ (203 Czech Republic), Gabor MEHES, Naveena SINGH, Simona STOLNICU, Petr SKAPA (203 Czech Republic), Marian SVAJDLER (203 Czech Republic), Ivana STRUZINSKA (203 Czech Republic), David CIBULA (203 Czech Republic), Roman KOCIAN (203 Czech Republic), Sigurd F. LAX, W Glenn MCCLUGGAGE and Pavel DUNDR (203 Czech Republic)

Edition

Diagnostic Pathology, LONDON, BMC, 2023, 1746-1596

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30109 Pathology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.600 in 2022

RIV identification code

RIV/00216224:14110/23:00130742

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1186/s13000-023-01300-4

UT WoS

000926120000002

Keywords in English

IMP2; IMP3; Ovarian carcinoma; Immunohistochemistry

Abstract

V originále

BackgroundIMP2 and IMP3 are mRNA binding proteins involved in carcinogenesis. We examined a large cohort of ovarian tumors with the aim to assess the value of IMP2 and IMP3 for differential diagnosis, and to assess their prognostic significance.MethodsImmunohistochemical analyses with antibodies against IMP2 and IMP3 were performed on 554 primary ovarian tumors including 114 high grade serous carcinomas, 100 low grade serous carcinomas, 124 clear cell carcinomas, 54 endometrioid carcinomas, 34 mucinous carcinomas, 75 mucinous borderline tumors, and 41 serous borderline tumors (micropapillary variant). The associations of overall positivity with clinicopathological characteristics were evaluated using the chi-squared test or Fisher's Exact test.ResultsWe found IMP2 expression (in more than 5% of tumor cells) in nearly all cases of all tumor types, so the prognostic meaning could not be analyzed. The positive IMP3 expression (in more than 5% of tumor cells) was most common in mucinous carcinomas (82%) and mucinous borderline tumors (81%), followed by high grade serous (67%) and clear cell carcinomas (67%). The expression was less frequent in endometrioid carcinomas (39%), low grade serous carcinomas (23%), and micropapillary variant of serous borderline tumors (20%). Prognostic significance of IMP3 could be evaluated only in low grade serous carcinomas in the case of relapse-free survival, where negative cases showed better RFS (p = 0.033).ConclusionConcerning differential diagnosis our results imply that despite the differences in expression in the different ovarian tumor types, the practical value for diagnostic purposes is limited. Contrary to other solid tumors, we did not find prognostic significance of IMP3 in ovarian cancer, with the exception of RFS in low grade serous carcinomas. However, the high expression of IMP2 and IMP3 could be of predictive value in ovarian carcinomas since IMP proteins are potential therapeutical targets.

Links

90125, large research infrastructures

Name: BBMRI-CZ III

Citovat

NEMEJCOVA, Kristyna, Michaela BARTU KENDALL, Romana MICHALKOVA, Jana DROZENOVA, Pavel FABIAN, Oluwole FADARE, Jitka HAUSNEROVÁ, Jan LACO, Radoslav MATEJ, Gabor MEHES, Naveena SINGH, Simona STOLNICU, Petr SKAPA, Marian SVAJDLER, Ivana STRUZINSKA, David CIBULA, Roman KOCIAN, Sigurd F. LAX, W Glenn MCCLUGGAGE and Pavel DUNDR. A comprehensive immunohistochemical analysis of IMP2 and IMP3 in 542 cases of ovarian tumors. Diagnostic Pathology. LONDON: BMC, 2023, vol. 18, No 1, p. 1-10. ISSN 1746-1596. Available from: https://dx.doi.org/10.1186/s13000-023-01300-4.

@article{2281360,
   author = {Nemejcova, Kristyna and Bartu Kendall, Michaela and Michalkova, Romana and Drozenova, Jana and Fabian, Pavel and Fadare, Oluwole and Hausnerová, Jitka and Laco, Jan and Matej, Radoslav and Mehes, Gabor and Singh, Naveena and Stolnicu, Simona and Skapa, Petr and Svajdler, Marian and Struzinska, Ivana and Cibula, David and Kocian, Roman and Lax, Sigurd F. and McCluggage, W Glenn and Dundr, Pavel},
   article_location = {LONDON},
   article_number = {1},
   doi = {http://dx.doi.org/10.1186/s13000-023-01300-4},
   keywords = {IMP2; IMP3; Ovarian carcinoma; Immunohistochemistry},
   language = {eng},
   issn = {1746-1596},
   journal = {Diagnostic Pathology},
   title = {A comprehensive immunohistochemical analysis of IMP2 and IMP3 in 542 cases of ovarian tumors},
   url = {https://diagnosticpathology.biomedcentral.com/articles/10.1186/s13000-023-01300-4},
   volume = {18},
   year = {2023}
}

TY  - JOUR
ID  - 2281360
AU  - Nemejcova, Kristyna - Bartu Kendall, Michaela - Michalkova, Romana - Drozenova, Jana - Fabian, Pavel - Fadare, Oluwole - Hausnerová, Jitka - Laco, Jan - Matej, Radoslav - Mehes, Gabor - Singh, Naveena - Stolnicu, Simona - Skapa, Petr - Svajdler, Marian - Struzinska, Ivana - Cibula, David - Kocian, Roman - Lax, Sigurd F. - McCluggage, W Glenn - Dundr, Pavel
PY  - 2023
TI  - A comprehensive immunohistochemical analysis of IMP2 and IMP3 in 542 cases of ovarian tumors
JF  - Diagnostic Pathology
VL  - 18
IS  - 1
SP  - 1-10
EP  - 1-10
PB  - BMC
SN  - 17461596
KW  - IMP2
KW  - IMP3
KW  - Ovarian carcinoma
KW  - Immunohistochemistry
UR  - https://diagnosticpathology.biomedcentral.com/articles/10.1186/s13000-023-01300-4
N2  - BackgroundIMP2 and IMP3 are mRNA binding proteins involved in carcinogenesis. We examined a large cohort of ovarian tumors with the aim to assess the value of IMP2 and IMP3 for differential diagnosis, and to assess their prognostic significance.MethodsImmunohistochemical analyses with antibodies against IMP2 and IMP3 were performed on 554 primary ovarian tumors including 114 high grade serous carcinomas, 100 low grade serous carcinomas, 124 clear cell carcinomas, 54 endometrioid carcinomas, 34 mucinous carcinomas, 75 mucinous borderline tumors, and 41 serous borderline tumors (micropapillary variant). The associations of overall positivity with clinicopathological characteristics were evaluated using the chi-squared test or Fisher's Exact test.ResultsWe found IMP2 expression (in more than 5% of tumor cells) in nearly all cases of all tumor types, so the prognostic meaning could not be analyzed. The positive IMP3 expression (in more than 5% of tumor cells) was most common in mucinous carcinomas (82%) and mucinous borderline tumors (81%), followed by high grade serous (67%) and clear cell carcinomas (67%). The expression was less frequent in endometrioid carcinomas (39%), low grade serous carcinomas (23%), and micropapillary variant of serous borderline tumors (20%). Prognostic significance of IMP3 could be evaluated only in low grade serous carcinomas in the case of relapse-free survival, where negative cases showed better RFS (p = 0.033).ConclusionConcerning differential diagnosis our results imply that despite the differences in expression in the different ovarian tumor types, the practical value for diagnostic purposes is limited. Contrary to other solid tumors, we did not find prognostic significance of IMP3 in ovarian cancer, with the exception of RFS in low grade serous carcinomas. However, the high expression of IMP2 and IMP3 could be of predictive value in ovarian carcinomas since IMP proteins are potential therapeutical targets.
ER  -

NEMEJCOVA, Kristyna, Michaela BARTU KENDALL, Romana MICHALKOVA, Jana DROZENOVA, Pavel FABIAN, Oluwole FADARE, Jitka HAUSNEROVÁ, Jan LACO, Radoslav MATEJ, Gabor MEHES, Naveena SINGH, Simona STOLNICU, Petr SKAPA, Marian SVAJDLER, Ivana STRUZINSKA, David CIBULA, Roman KOCIAN, Sigurd F. LAX, W Glenn MCCLUGGAGE and Pavel DUNDR. A comprehensive immunohistochemical analysis of IMP2 and IMP3 in 542 cases of ovarian tumors. \textit{Diagnostic Pathology}. LONDON: BMC, 2023, vol.~18, No~1, p.~1-10. ISSN~1746-1596. Available from: https://dx.doi.org/10.1186/s13000-023-01300-4.

Detailed Information on Publication Record